Shandong Weigao Group (1066.HK) Q4 2025 Earnings Report

Shandong Weigao Group Medical Polymer delivered a robust Q4 2025 with revenue of 6.63 billion CNY and a solid gross margin, underscoring ongoing demand for its diversified medical device portfolio. The quarter produced net income of 593.8 million CNY and basic earnings per share of 0.13, with EBITDA of 1.19 billion CNY and an EBIT margin of about 10.6%. On a YoY basis, the company reported notable margin expansion and earnings strength, although QoQ the quarter reflected a seasonal(ish) deceleration in operating momentum and a material step-down in quarterly profitability metrics from the prior quarter. Liquidity remains a key strength: cash and short-term investments total approximately 9.87 billion CNY, with a net debt position of about -2.999 billion CNY, and a current ratio near 3.8. Balance sheet metrics show a high level of working capital efficiency, supported by a large net receivables base and meaningful inventory levels that reflect the company’s scale and product breadth across orthopaedic, interventional, and blood management segments.

Management commentary to the extent available in the release emphasizes continued focus on core device categories, R&D investment, and capacity optimization to support mid-to-long-term growth, though explicit forward-looking targets were not disclosed in the provided materials.